RARE Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Ultragenyx Pharmaceutical Inc. (RARE)

Core Viewpoint - A securities fraud class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. (RARE) for alleged material misstatements and omissions regarding its drug setrusumab, affecting investors who purchased stock between August 3, 2023, and December 26, 2025 [1] Summary by Relevant Sections Lawsuit Details - The lawsuit is filed in the United States District Court for the Northern District of California, under the case name Bailey v. Ultragenyx Pharmaceutical Inc., Case No. 3:26-cv-01097 (N.D. Cal.) [1] - Investors have until April 6, 2026, to file for lead plaintiff status [1] Allegations - The complaint alleges that Ultragenyx misrepresented the reliability of information regarding the effects of setrusumab on patients with Osteogenesis Imperfecta, downplaying the risks associated with the Phase III Orbit study [1] - It is claimed that Ultragenyx's optimism regarding the study results was unfounded, as the Phase II results lacked a placebo control group, raising concerns about the validity of the reported reduction in annualized fracture rate (AFR) [1] - The lawsuit asserts that the positive statements made by Ultragenyx about its business and prospects were materially misleading and lacked a reasonable basis [1] Investor Actions - Investors are advised to retain counsel or contact Kessler Topaz Meltzer & Check, LLP for a free case evaluation [1] - The process for becoming a lead plaintiff is outlined, emphasizing that the lead plaintiff represents the interests of all class members [1]